COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes

BACKGROUND: In a Phase 3 prevention trial, the monoclonal antibody combination casirivimab and imdevimab (REGEN-COVTM) administered subcutaneously (SC) prevented symptomatic SARS-CoV-2 infection in asymptomatic adults/adolescents living in the same household as a SARS-CoV-2-infected individual (inde...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Brien, Meagan P., Forleo-Neto, Eduardo, Musser, Bret J., Isa, Flonza, Chan, Kuo-Chen, Sarkar, Neena, Bar, Katharine J., Barnabas, Ruanne V., Barouch, Dan H., Cohen, Myron S., Marovich, Mary A., Hou, Peijie, Heirman, Ingeborg, Davis, John D., Turner, Kenneth C., Ramesh, Divya, Mahmood, Adnan, Purcell, Lisa, Hooper, Andrea T., Hamilton, Jennifer D., Kim, Yunji, Baum, Alina, Kyratsous, Christos A., Krainson, James, Perez-Perez, Richard, Mohseni, Rizwana, Kowal, Bari, DiCioccio, A. Thomas, Stahl, Neil, Lipsich, Leah, Braunstein, Ned, Herman, Gary, Yancopoulos, George D., Weinreich, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Mosby, Inc. 2021
Materias:
0099
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556497/
http://dx.doi.org/10.1016/j.ahj.2021.10.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556497/
http://dx.doi.org/10.1016/j.ahj.2021.10.067

Ejemplares similares